Lactate and Glycerol Contribution to Gluconeogenesis

Phase 1

Not yet recruiting

• Conditions: Type 2 Diabetes; Obesity; Healthy
• Interventions: Drug: Glycerol; Drug: Glucose; Drug: Lactate

• Registration Number: NCT06955130
• Lead Sponsor: Rutgers, The State University of New Jersey

Brief Summary

A major cause of increased blood glucose levels in type 2 diabetes (T2D) is increased hepatic gluconeogenesis (GNG), as the liver converts various substrates into glucose. Two of these substrates include glycerol, a molecule from fat, and lactate, a molecule that circulates in the blood. Our previously collected data suggest that glycerol's role in this process has been underestimated, so the investigators will directly compare the carbon contribution of glycerol and lactate to new glucose production under fasting conditions in patients with and without T2D. The investigators will also assess how glucagon, a hormone that raises blood glucose levels, impacts the conversion of glycerol and lactate to glucose. Enrolled participants will undergo three separate isotope tracer infusions with serial blood collections for liquid chromatography-mass spectrometry analysis. This research could identify new therapeutic drug targets that can lower blood glucose levels more directly and effectively.

Detailed Description

Objectives:

1. Compare glycerol and lactate as carbon sources for GNG in humans with and without T2D.

2. Compare the contribution of glycerol and lactate to GNG during a hyperglucagonemic state.

Hypothesis:

1. Glycerol contributes to glucose and lactate production, while lactate only contributes to glucose production.

2. Glycerol, not lactate, potentiates the observed increases in GNG seen in T2D.

3. Glucagon promotes greater glycerol incorporation into glucose as compared to lactate incorporation into glucose.

Study Design:

The investigators will recruit three different adult metabolic cohorts (16 per cohort): 1) Lean, defined as body mass index (BMI) \<25.0 kg/m2, and no T2D; 2) Obese (BMI ≥ 30.0 kg/m2) and no T2D; and 3) Obese (BMI ≥ 30.0 kg/m2) and with T2D. All subjects will be between the ages of 18 and 65. All subjects will perform a self-monitored overnight fast at home and then come for three separate isotope tracer infusions (13C3-glycerol, 13C3-lactate, and 13C6-glucose) with serial blood draws. Each tracer infusion will last eight hours. During the final two hours of the infusion, subjects will receive intravenous glucagon, which increases the amount of glucose the liver produces. Collected blood samples will undergo liquid chromatography-mass spectrometry (LC-MS) analysis in our laboratory. Additionally, all subjects will receive a body composition analysis via dual-energy X-ray absorptiometry (DXA).

Study Timeline

• Study First Submitted: 2025-04-24
• Study First Submitted QC: 2025-04-24
• Status Verified: 2025-05
• Study First Posted: 2025-05-02
• Last Update Submitted: 2025-05-07
• Last Update Posted: 2025-05-13
• Study Start: 2025-08-01
• Primary Completion: 2028-05-31
• Study Completion: 2029-05-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Glycerol	Glycerol	Each subject will receive labeled 13C3-glycerol.
Glucose	Glucose	Each subject will receive labeled 13C6-glucose.
Lactate	Lactate	Each subject will receive labeled 13C3-lactate.

Primary Outcome Measures

Name	Time	Method
Carbon Contribution to Glucose Production	8 hours	Net carbon flux from glycerol and lactate to glucose will be measured using LC-MS of plasma glucose via 13C-enrichment after infusion of various metabolic tracers